Propeller Health has received US FDA 510(k) clearance to market its Propeller platform in association with medications using GlaxoSmithKline’s Diskus dry powder inhaler (DPI) device for asthma and COPD.
Propeller is an FDA-cleared digital health platform designed to help patients and their physicians better understand asthma and COPD, and help to improve the symptoms and outcomes of these chronic respiratory diseases.
Propeller’s platform remotely monitors use of inhaled rescue and controller medications in asthma and COPD, analyzes patient trends, and provides regular feedback. The Propeller system has FDA-granted claims to increase adherence to therapy, predict oncoming exacerbations and help reduce the frequency of symptoms and exacerbations in asthma and COPD.
Under the 510(k) clearances, the Propeller system can now be used in association with medications delivered by Boehringer Ingelheim’s Respimat device (such as Spiriva Respimat, Combivent Respimat, Striverdi Respimat, Stiolto Respimat) and dry powder inhaler (DPI) medications utilizing GlaxoSmithKline’s Diskus device (such as Advair Diskus, Flovent Diskus, Serevent Diskus).